Asian CPP needs continue but flexibility improving
This article was originally published in Scrip
Executive Summary
The need to provide certificates of pharmaceutical product (CPP) to many drug regulatory authorities in Asia is seen by some in the industry as a major hindrance to the simultaneous global development of new drugs. But views from regional regulators at a recent Asia-Pacific Economic Cooperation (APEC) symposium suggest that there is little prospect of the requirement disappearing anytime soon.